Advanced fPAT Imaging Inc.
A NEW NON-RADIATION BASED BREAST IMAGING PLATFORM FOR EARLY BREAST CANCER DETECTION, addressing the growing dissatisfaction with mammography’s diagnostic accuracy.
Advanced fPAT Imaging Inc. is commercializing the JBI-360, the first breast imaging device to incorporate Functional PhotoAcoustic Tomography (fPAT). Developed at the University of Florida, fPAT offers an imaging alternative that does not have the loss of diagnostic accuracy in dense breast tissue that mammography faces. Over 50% of the population have dense breast tissue and should not rely on mammography for breast cancer screening. The JBI-360 provides a comfortable imaging experience that does not require radiation, injections of contrast agents, or painful breast compression.
AfPII’s management team strongly feels that fPAT imaging will have the same impact that CT and MRI had on the diagnostic imaging community. The diagnostic imaging marketplace exceeds $32B in 2015 and will grow to over $49B by 2020. To enter this market, AfPII is soliciting a seed capital investment of $300,000 to $500,000. The Florida Institute for the Commercialization of Public Research will match this seed investment up to $300K. AfPII has developed an excellent set of documents that describe this new imaging technology and the potential for substantial returns that can be realized from a seed capital investment. For additional information, please contact Michael Addley, CEO, at email@example.com or 954.338.4635.
Products / Services
The JBI-360 Breast Imaging System
The JBI-360 Breast Imaging System (pat. pend.) incorporates new Functional PhotoAcoustic Tomography technology whose diagnostic accuracy is not affected by breast tissue density. The technique uses pulses of laser light and sensitive ultrasound detectors to create high-resolution images of Optical Absorption, Oxygenated and Deoxygenated Hemoglobin, and Oxygen Saturation within the breast. For the first time, the Radiologist and Oncologist will have a noninvasive technique that provides both anatomical and physiological information (at the cellular level) about possible cancers within the breast without the use of ionizing radiation or contrast agents.
The JBI-360 is demonstrating superiority over both MRI and mammography in early clinical trials, especially when imaging dense breast tissue. Recent clinical studies show that the JBI-360 could provide a new, more accurate diagnostic tool for radiologists trying to see and diagnose cancer earlier, especially through dense breast tissue.